Updates are available Correction dated 2024-11-15
Click to view Correction: https://doi.org/10.1038/s41591-024-03404-w
-
Authors
Horwitz, Steven M. https://orcid.org/0000-0002-6399-2006
Nirmal, Ajit J. https://orcid.org/0000-0003-4139-0618
Rahman, Jahan https://orcid.org/0000-0001-8755-5890
Xu, Ran https://orcid.org/0000-0001-5023-3281
Drill, Esther https://orcid.org/0000-0002-3315-4538
Galasso, Natasha
Ganesan, Nivetha
Davey, Theresa
Hancock, Helen
Perez, Leslie
Maccaro, Catherine
Bahgat, Alexandra
Marzouk, Evan
Cathcart, Elizabeth
Moskowitz, Alison
Noy, Ariela
Kumar, Anita
Jacobsen, Eric
Fisher, David C. https://orcid.org/0000-0001-6915-8584
Mehta-Shah, Neha
Kim, Youn H.
Khodadoust, Michael
Kotlov, Nikita https://orcid.org/0000-0002-6393-7357
Nikitina, Anastasia
Kudryashova, Olga https://orcid.org/0000-0003-3320-7764
Zubareva, Valeria
Zornikova, Ksenia
Shin, Nara https://orcid.org/0000-0002-9910-4971
Sorokina, Maria https://orcid.org/0000-0003-1541-9480
Degryse, Sandrine
Postovalova, Ekaterina https://orcid.org/0000-0002-3413-3122
Bagaev, Aleksander
Hosszu, Kinga https://orcid.org/0000-0002-1190-1491
McAvoy, Devin
Boelens, Jaap J. https://orcid.org/0000-0003-2232-6952
Wu, Wenchao
Ciantra, Zoe
Appelt, Jackson W.
Trevisani, Christopher https://orcid.org/0009-0005-2112-1148
Amaka, Sam
Weinstock, David M. https://orcid.org/0000-0002-8724-3907
Vardhana, Santosha A. https://orcid.org/0000-0002-3100-1298
- License Information
-
More Information
Article History
Received: 3 January 2024
Accepted: 17 May 2024
First Online: 17 June 2024
Change Date: 15 November 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-024-03404-w
Competing interests
: D.M.W. is an employee of Merck and Co.; owns equity in Merck and Co., Bantam, Ajax and Travera; received consulting fees from AstraZeneca, Secura Bio, Novartis and Roche/Genentech; and received research support from Daiichi Sankyo, AstraZeneca, Verastem, AbbVie, Novartis, Abcura and Surface Oncology. S.A.V. has served as an advisor for Immunai and has received consulting fees from ADC Therapeutics and Koch Disruptive Technologies. J.J.B. received consulting fees from Sobi, Omeros, Bluebird Bio, Sanofi, Immusoft, SmartImmune, Bluerock and Advanced Clinical. N.M.-S. has received institutional clinical trial funding from AstraZeneca, Bristol Myers Squibb, Celgene, C4 Therapeutics, Corvus Pharmaceuticals, Daiichi Sankyo, Genentech/Roche, Innate Pharmaceuticals, Secura Bio/Verastem, Yingli Pharmaceuticals and Dizal Pharmaceuticals. N.M.-S. has also received compensation for service as a consultant for AstraZeneca, Secura Bio/Verastem, Daiichi Sankyo, C4 Therapeutics, Genentech, Janssen, Karyopharm Therapeutics and Kyowa Hakko Kirin. N.M.-S. is funded as a Scholar in Clinical Research through the Leukemia & Lymphoma Society, and this study was reviewed as part of the ASCO/AACR Workshop. S.M.H. has received research support from ADC Therapeutics, Affimed, C4, Celgene, CRISPR Therapeutics, Daiichi Sankyo, Dren, Kyowa Hakko Kirin, Millennium/Takeda, Seattle Genetics and Secura Bio. S.M.H. has also received consulting fees from Affimed, Abcuro, Corvus, Daiichi Sankyo, Kyowa Hakko Kirin, ONO Pharmaceuticals, SeaGen, Secura Bio, Takeda and Yingli Pharmaceuticals. A.J.M. has received research support from BeiGene, Seattle Genetics, Merck, Bristol Myers Squibb, Incyte, Affimed and AstraZeneca. A.J.M. has also received consulting fees from Affimed, Merck, Seattle Genetics and Takeda. The remaining authors declare no competing interests.
